

1 **Title:** Association of Increased Fluvoxamine Use with Reports of Benefit for COVID

2

3 **Authors:** Kojima N¹, Dima M Qato²⁻³ and Klausner JD⁴

4

5 ¹ Department of Medicine, University of California Los Angeles, Los Angeles, 90095

6 ² Program on Medicines and Public Health, Department of Clinical Pharmacy, University
7 of Southern California, School of Pharmacy, Los Angeles, California

8 ³ Schaeffer Center for Health Policy and Economics, University of Southern California,
9 Los Angeles, California

10 ⁴ Department of Population and Public Health Sciences, University of Southern
11 California, Keck School of Medicine, Los Angeles, 90033

12

13 **Keywords:** COVID-19; SARS-CoV-2; Vaccination; Prior infection

14

15

16

17

18

19

20 **Corresponding Author Contact Information:**

21 Department of Medicine at UCLA, 10833 Le Conte Ave, Los Angeles, CA

22 90095. Email: nkojima@ucla.edu

23

24 **Abstract**

25 Introduction: Several recent studies have found that fluvoxamine decreases the risk of
26 serious disease progression among people with early SARS-CoV-2 infection. In this
27 study, we examined changes in the total number of fluvoxamine tablets dispensed
28 across retail pharmacies in the U.S.

29 Methods: We hypothesized that fluvoxamine prescriptions would increase substantially
30 since March 2021 as an option for the early treatment of SARS-CoV-2 infection. We
31 used the IQVIA National Prescription Audit (NPA) Weekly nationally projected data for
32 prescriptions dispensed from retail pharmacies for fluvoxamine from 27 December 2019
33 to 31 December 2021. We performed an interrupted-time series analyses on frequency
34 of dispensing fluvoxamine tablets.

35 Results: The weekly rate of dispensed tablets of fluvoxamine increased throughout the
36 study period. The weekly number of dispensed tablets of fluvoxamine increased
37 (11.1%) from a baseline of 1,586,154 (95% confidence interval [CI]: 1,563,960 –
38 1,608,348) to 1,762,381 (95% CI: 1,735,682 – 1,789,080) by December 2021.

39 Conclusion: Our findings are consistent with a modest increase in the use of
40 fluvoxamine for the treatment of COVID-19 associated with the discovery and media
41 dissemination of the potential clinical benefit of fluvoxamine use.

42

43 **Main Text**

44 Several recent studies have found that fluvoxamine decreases the risk of serious
45 disease progression among people with early SARS-CoV-2 infection.¹⁻³ In March 2021 a
46 widely watched news program aired a report describing the potential benefit of
47 fluvoxamine for COVID-19.⁴ While several medications were developed to treat COVID-
48 19, repurposing existing medications like fluvoxamine offer benefits, including
49 widespread availability, known safety profiles, and low cost, that newly approved
50 medications lack.⁵ In this study, we examined changes in the total number of
51 fluvoxamine tablets dispensed across retail pharmacies in the U.S. We hypothesized
52 that fluvoxamine prescriptions would increase substantially since March 2021 as an
53 option for the early treatment of SARS-CoV-2 infection.

54
55 We used the IQVIA National Prescription Audit (NPA) Weekly nationally projected data
56 for prescriptions dispensed from retail pharmacies for fluvoxamine from 27 December
57 2019 to 31 December 2021. The NPA aggregates prescription data from pharmacies
58 across the US representing approximately 92% of all retail prescription activity. We
59 performed an interrupted-time series analyses on frequency of dispensing fluvoxamine
60 tablets. The potential clinical benefit of fluvoxamine for COVID-19 was widely
61 disseminated on 7 March 2021, therefore we compared periods from 27 December
62 2019 to 3 March 2021 and from 12 March to 31 December 2021. Adjustment for first-
63 order autocorrelation was made through autoregressive integrated moving average
64 models. The weekly number of dispensed tablets of fluvoxamine were compared

65 between periods. Analyses were performed on StataSE (StataCorp, College Station,
66 TX).

67
68 The weekly rate of dispensed tablets of fluvoxamine increased throughout the study
69 period. The weekly number of dispensed tablets of fluvoxamine increased (11.1%) from
70 a baseline of 1,586,154 (95% confidence interval [CI]: 1,563,960 – 1,608,348) to
71 1,762,381 (95% CI: 1,735,682 – 1,789,080) by December 2021 (Figure).

72
73 Our findings are consistent with a modest increase in the use of fluvoxamine for the
74 treatment of COVID-19 associated with the discovery and media dissemination of the
75 potential clinical benefit of fluvoxamine use. Other events, however, may have
76 contributed to this temporal trend. For instance, there may have also been increased
77 fluvoxamine prescription for the treatment of depression, which is also associated with
78 COVID-19. However, the increased use of fluvoxamine was non-linear and appeared to
79 rapidly increase after increased awareness of its potential COVID-19 treatment benefit.
80 Nevertheless, as an ecological study, our results are preliminary and should be
81 confirmed with additional studies.

82 83 **Declarations**

84 Declaration of competing interests

85 None

86 87 **Funding**

88 Supported in part by a gift to the Keck School of Medicine of the University of
89 Southern California by the W.M. Keck Foundation.

90

91 **Acknowledgements**


92 This study was supported, in part, through the IQVIA Institute Human Data Science
93 Research Collaborative. The statements, findings, conclusions, views, and opinions
94 contained and expressed herein are not necessarily those of IQVIA or any of its
95 affiliated or subsidiary entities

96

97 **References**

- 98 1. Lenze EJ, Mattar C, Zorumski CF, et al. Fluvoxamine vs Placebo and Clinical
99 Deterioration in Outpatients With Symptomatic COVID-19: A Randomized
100 Clinical Trial. JAMA 2020;324(22):2292-2300. DOI: 10.1001/jama.2020.22760.
- 101 2. Seftel D, Boulware DR. Prospective Cohort of Fluvoxamine for Early Treatment
102 of Coronavirus Disease 19. Open Forum Infect Dis 2021;8(2):ofab050. DOI:
103 10.1093/ofid/ofab050.
- 104 3. Reis G, Dos Santos Moreira-Silva EA, Silva DCM, et al. Effect of early treatment
105 with fluvoxamine on risk of emergency care and hospitalisation among patients
106 with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob
107 Health 2022;10(1):e42-e51. DOI: 10.1016/S2214-109X(21)00448-4.
- 108 4. Alfonsi S. Finding a possible early treatment for COVID-19 in a 40-year-old
109 antidepressant. 60 Minutes. CBS, 2021.
110 [\(https://www.cbsnews.com/news/fluvoxamine-antidepressant-drug-covid-](https://www.cbsnews.com/news/fluvoxamine-antidepressant-drug-covid-treatment-60-minutes-2021-03-07/)
111 [treatment-60-minutes-2021-03-07/](https://www.cbsnews.com/news/fluvoxamine-antidepressant-drug-covid-treatment-60-minutes-2021-03-07/)).
- 112 5. Facente SN, Reiersen AM, Lenze EJ, Boulware DR, Klausner JD. Fluvoxamine
113 for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence.
114 Drugs 2021;81(18):2081-2089. DOI: 10.1007/s40265-021-01636-5.
115

116 Figure. Trends in the total number of dispensed tablets of fluvoxamine in retail, mail, and long-term care pharmacies in the
117 U.S., 27 December 2019 to 31 December 2021



118
119 *ARIMA regression of 3,234.2 (95% CI: 1,936.8 – 4,531.6; $p < 0.001$).